Last reviewed · How we verify
AD-221A and AD-221B
AD-221A and AD-221B is a Small molecule drug developed by Addpharma Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | AD-221A and AD-221B |
|---|---|
| Sponsor | Addpharma Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A (PHASE3)
- A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD-221A and AD-221B CI brief — competitive landscape report
- AD-221A and AD-221B updates RSS · CI watch RSS
- Addpharma Inc. portfolio CI
Frequently asked questions about AD-221A and AD-221B
What is AD-221A and AD-221B?
AD-221A and AD-221B is a Small molecule drug developed by Addpharma Inc..
Who makes AD-221A and AD-221B?
AD-221A and AD-221B is developed by Addpharma Inc. (see full Addpharma Inc. pipeline at /company/addpharma-inc).
What development phase is AD-221A and AD-221B in?
AD-221A and AD-221B is in Phase 1.
Related
- Manufacturer: Addpharma Inc. — full pipeline
- Compare: AD-221A and AD-221B vs similar drugs
- Pricing: AD-221A and AD-221B cost, discount & access